Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3783-3785

  Thompson III, George R ^a   Wiederhold, Nathan P ^a,c   Vallor, Ana C ^a   Villareal, Nyria C ^a   Lewis II, James S ^a,b   Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; GLUCAN SYNTHASE; MICAFUNGIN;

ABDOMINAL ABSCESS; ADULT; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; DEATH; FUNGUS CULTURE; FUNGUS MUTATION; HUMAN; LOADING DRUG DOSE; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PERITONEAL FLUID; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA; SEQUENCE ANALYSIS;

ADULT; AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA GLABRATA; CANDIDIASIS; DNA PRIMERS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GENES, FUNGAL; GLUCOSYLTRANSFERASES; HUMANS;

EID: 54049093652     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00473-08     Document Type: Article

References (25)

1. Bautista-Muñoz, C., X. M. Boldo, L. Villa-Tanaca, and C. Hernández-Rodriguez. 2003. Identification of Candida spp. by randomly amplified polymorphic DNA analysis and differentiation between Candida albicans and Candida dubliniensis by direct PCR methods. J. Clin. Microbiol. 41:414-420.
2. Becker, K., D. Badehorn, S. Deiwick, G. Peters, and W. Fegeler. 2000. Molecular genotyping of Candida species with special respect to Candida (Torulopsis) glabrata strains by arbitrarily primed PCR. J. Med. Microbiol. 49:575-581.
3. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
4. Cota, J., M. Carden, J. R. Graybill, L. K. Najvar, D. S. Burgess, and N. P. Wiederhold. 2006. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. 50:3926-3928.
5. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
6. Douglas, C. M., J. A. Marrinan, W. Li, and M. B. Kurtz. 1994. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase. J. Bacteriol. 176:5686-5696.
7. Hernandez, S., J. L. López-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
8. Kahn, J. N., G. Garcia-Effron, M.-J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
9. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
10. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
11. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.
12. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
13. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
14. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.
15. Mochizuki, N., M. Aibiki, and Y. Matsumoto. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1598, p. 423.
16. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
17. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
19. Paderu, P., G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
20. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
21. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
22. Pelletier, R., I. Alarie, R. Lagace, and T. J. Walsh. 2005. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43:559-564.
23. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
24. Villareal, N. C., A. W. Fothergill, C. Kelly, J. E. Patterson, M. G. Rinaldi, and T. F. Patterson. 2004. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1034, p. 417.
25. Wiederhold, N. P., L. K. Najvar, R. Bocanegra, D. Molina, M. Olivo, and J. R. Graybill. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620.